Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Blood
; 135(25): 2224-2234, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232481
3.
Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
Blood
; 133(2): 121-129, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30429158
4.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 106(9): 2364-2373, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730844
5.
Current Role of Functional Imaging in the Management of Lymphoma.
Curr Oncol Rep
; 23(12): 144, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735647
6.
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1414-1424, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325171
7.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682002
8.
A man's best friend is his PET.
Blood
; 141(25): 3010-3012, 2023 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347501
9.
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Blood
; 132(10): 1013-1021, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30049811
10.
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Blood
; 131(25): 2745-2760, 2018 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29540348
11.
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
Am J Hematol
; 95(6): 583-593, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32170769
12.
Copanlisib in the treatment of non-Hodgkin lymphoma.
Future Oncol
; 16(26): 1947-1955, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32658557
13.
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Clin Adv Hematol Oncol
; 18 Suppl 10(6): 1-20, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843867
14.
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Cancer
; 125(19): 3378-3389, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31174236
15.
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
Br J Haematol
; 185(1): 53-64, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30723894
16.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica
; 104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923097
17.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(1): 65-75, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29246803
18.
Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
Blood
; 128(3): 325-30, 2016 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27222479
19.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Blood
; 128(21): 2489-2496, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27574190
20.
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Blood
; 128(21): 2510-2516, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27697771